Fidelity International
SPRY icon

Fidelity International’s ARS Pharmaceuticals SPRY Stock Holding History

Fidelity International’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.65M Hold
455,575
– – ﹤0.01% 724
2026
Q1 		$3.66M Sell
455,575
-354,498
-44% -$3.4M ﹤0.01% 721
2025
Q4 		$9.44M Buy
+810,073
New +$7.88M 0.01% 593

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity International's SPRY Position: Q2 2026 in Review

Fidelity International held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 455,575 shares worth $3.65M. The position accounts for ﹤0.01% of the portfolio, ranked #724.

Fidelity International first reported a position in SPRY in Q4 2025 and has held it in 3 quarters since. The position peaked at $9.44M in Q4 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Fidelity International held 455,575 shares of ARS Pharmaceuticals worth $3.65M as of Q2 2026.
  • Fidelity International left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Fidelity International's portfolio in Q2 2026, its #724 holding.
  • Fidelity International first reported a position in ARS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Fidelity International's ARS Pharmaceuticals position peaked at $9.44M in Q4 2025.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Fidelity International's 13F filing for Q2 2026, filed 13 Aug 2026.